Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152


Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR.

Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6.


Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, Dyer M, Matutes E, Gonzalez D, Taylor AM, Moss P, Thomas P, Oscier D, Stankovic T.

J Clin Oncol. 2012 Dec 20;30(36):4524-32. doi: 10.1200/JCO.2011.41.0852. Epub 2012 Oct 22.


Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.

Lossaint G, Besnard E, Fisher D, Piette J, Dulić V.

Oncogene. 2011 Oct 13;30(41):4261-74. doi: 10.1038/onc.2011.135. Epub 2011 May 2.


p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T.

Blood. 2001 Aug 1;98(3):814-22.


Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM, Moss PA, Stankovic T.

J Clin Oncol. 2007 Dec 1;25(34):5448-57. Epub 2007 Oct 29.


The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.

Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP.

Leuk Lymphoma. 2012 Jul;53(7):1367-75. doi: 10.3109/10428194.2011.647310. Epub 2012 Jan 31.


A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer MJ, Oscier DG.

Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17. No abstract available.


Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S.

Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.


Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ.

J Clin Oncol. 2011 Jun 1;29(16):2223-9. doi: 10.1200/JCO.2010.32.0838. Epub 2011 Apr 11.


Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.

Xu W, Li JY, Wu YJ, Yu H, Shen QD, Li L, Fan L, Qiu HX.

Leuk Res. 2008 Jul;32(7):1071-7. Epub 2007 Nov 26.


Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.

Cejkova S, Rocnova L, Potesil D, Smardova J, Novakova V, Chumchalova J, Zezulkova D, Borsky M, Doubek M, Brychtova Y, Pospisilova S, Klabusay M, Mayer J, Trbusek M.

Eur J Haematol. 2009 Feb;82(2):133-42. doi: 10.1111/j.1600-0609.2008.01177.x. Epub 2008 Nov 6.


A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity.

Kabacik S, Ortega-Molina A, Efeyan A, Finnon P, Bouffler S, Serrano M, Badie C.

Cell Cycle. 2011 Apr 1;10(7):1152-61. Epub 2011 Apr 1.


Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC.

Leuk Lymphoma. 2012 Sep;53(9):1743-8. doi: 10.3109/10428194.2012.668683. Epub 2012 Jun 2.


[Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].

Yu GZ, Zhu MH, Chen Y, Ni CR, Li FM.

Ai Zheng. 2005 Nov;24(11):1398-403. Chinese.


The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function.

Lo PK, Lee JS, Sukumar S.

Cell Signal. 2012 Jan;24(1):316-24. doi: 10.1016/j.cellsig.2011.09.017. Epub 2011 Sep 22.


A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, Lane DP, Hubank M, Powell JE, Wei W, Taylor AM, Moss PA, Stankovic T.

Blood. 2005 Jun 1;105(11):4484-91. Epub 2005 Feb 3.


UVB-Induced p21 degradation promotes apoptosis of human keratinocytes.

Lei X, Liu B, Han W, Ming M, He YY.

Photochem Photobiol Sci. 2010 Dec;9(12):1640-8. doi: 10.1039/c0pp00244e. Epub 2010 Oct 8.


Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.

Carter A, Lin K, Sherrington PD, Pettitt AR.

Br J Haematol. 2004 Nov;127(4):425-8.


Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group.

Lancet. 2007 Jul 21;370(9583):230-239. doi: 10.1016/S0140-6736(07)61125-8.


Supplemental Content

Support Center